The Maternal Autoimmune Disease Research Alliance (MADRA) Registry is an observational study for women with autoimmune diseases who are planning to become pregnant or are currently pregnant. This registry aims to understand how autoimmune conditions like lupus (systemic lupus erythematosus or cutaneous lupus), rheumatoid arthritis, and others affect pregnancy outcomes. Researchers will collect information from your regular doctor visits during pregnancy and up to 12 months after delivery. The goal is to identify risk factors that lead to poor pregnancy outcomes, measured by a questionnaire called MADRA-DAP, over a period of up to 10 years. This study does not involve new medications or procedures beyond your usual care.

Study design

This is an observational study, meaning it collects information without testing new treatments. It plans to enroll 1000 women.

What's involved

You would continue your standard medical care with your rheumatologist and obstetrician. Data from your office visits during pregnancy and up to 12 months after delivery will be collected.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, risk factors associated with poor pregnancy outcomes, will be measured at up to 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.